Cardiac amyloidosis MRI: Difference between revisions

Jump to navigation Jump to search
Line 7: Line 7:


==MRI==
==MRI==
CMR findings in cardiac amyloidosis include:
CMR findings in cardiac amyloidosis include:<ref name="pmid20083070">{{cite journal |author=Austin BA, Tang WH, Rodriguez ER, ''et al.'' |title=Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis |journal=[[JACC. Cardiovascular Imaging]] |volume=2 |issue=12 |pages=1369–77 |year=2009 |month=December |pmid=20083070 |doi=10.1016/j.jcmg.2009.08.008 |url=}}</ref>
* Signal enhancement in the late washout phase during delayed enhanced imaging
* Signal enhancement in the late washout phase during delayed enhanced imaging
* Increased gadolinium wash-out time
* Increased gadolinium wash-out time

Revision as of 18:53, 4 May 2013

Cardiac amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiac Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac amyloidosis MRI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac amyloidosis MRI

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac amyloidosis MRI

CDC onCardiac amyloidosis MRI

Cardiac amyloidosis MRI in the news

Blogs on Cardiac amyloidosis MRI

Directions to Hospitals Treating Cardiac amyloidosis

Risk calculators and risk factors for Cardiac amyloidosis MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Aarti Narayan, M.B.B.S [3]

Overview

Amyloidosis is an infiltrative disease resulting in deposition of amyloid in the extracellular spaces of the tissues. Amyloid infiltration of the heart leads to expansion of these extracellular spaces resulting in retainment of gadolinium dye during cardiac magnetic resonance imaging. This retainment of gadolinium leads to signal enhancement in the late washout phase during delayed enhanced cardiac imaging.

MRI

CMR findings in cardiac amyloidosis include:[1]

  • Signal enhancement in the late washout phase during delayed enhanced imaging
  • Increased gadolinium wash-out time
  • Brighter appearance of the myocardium compared to normal myocardium

ACC/AHA Guidelines- ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance[2] (DO NOT EDIT)

CMR may be used for assessment of patients with LV dysfunction or hypertrophy or suspected forms of cardiac injury not related to ischemic heart disease. When the diagnosis is unclear, CMR may be considered to identify the etiology of cardiac dysfunction in patients presenting with heart failure, including

References

  1. Austin BA, Tang WH, Rodriguez ER; et al. (2009). "Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis". JACC. Cardiovascular Imaging. 2 (12): 1369–77. doi:10.1016/j.jcmg.2009.08.008. PMID 20083070. Unknown parameter |month= ignored (help)
  2. American College of Cardiology Foundation Task Force on Expert Consensus Documents. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA; et al. (2010). "ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents". Circulation. 121 (22): 2462–508. doi:10.1161/CIR.0b013e3181d44a8f. PMC 3034132. PMID 20479157.


Template:WikiDoc Sources